Malinger
发表于 2025-3-21 18:44:29
书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0390910<br><br> <br><br>书目名称Guide to Targeted Therapies: EGFR mutations in NSCLC读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0390910<br><br> <br><br>
匍匐前进
发表于 2025-3-22 00:14:14
http://reply.papertrans.cn/40/3910/390910/390910_2.png
FISC
发表于 2025-3-22 01:44:57
http://reply.papertrans.cn/40/3910/390910/390910_3.png
Ancillary
发表于 2025-3-22 05:03:44
http://reply.papertrans.cn/40/3910/390910/390910_4.png
独轮车
发表于 2025-3-22 10:17:31
http://reply.papertrans.cn/40/3910/390910/390910_5.png
哑巴
发表于 2025-3-22 13:57:39
http://reply.papertrans.cn/40/3910/390910/390910_6.png
哑巴
发表于 2025-3-22 18:02:21
http://reply.papertrans.cn/40/3910/390910/390910_7.png
旋转一周
发表于 2025-3-22 21:21:11
http://reply.papertrans.cn/40/3910/390910/390910_8.png
慢慢冲刷
发表于 2025-3-23 04:39:56
The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function,r 1 ), HER2 (c-ErbB-2), HER3 (c-ErbB-3), and HER4 (c-ErbB-4). These proteins are coded by distinct genes that are expressed on chromosomes 7, 17, 12, and 2, respectively. Although specific soluble ligands have been identified for the extracellular domains of EGFR, HER3, and HER4, no ligand has been identified for HER2.
胡言乱语
发表于 2025-3-23 09:34:25
Conclusions,. In patients with non-small cell lung cancer (NSCLC) it is now mandatory to evaluate . (.) mutation status before treatment choice and EGFR tyrosine kinase inhibitors (TKIs) are the optimal option in the patients harboring activating . mutations.